CN113480512B - Preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-ketone - Google Patents

Preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-ketone Download PDF

Info

Publication number
CN113480512B
CN113480512B CN202110839803.6A CN202110839803A CN113480512B CN 113480512 B CN113480512 B CN 113480512B CN 202110839803 A CN202110839803 A CN 202110839803A CN 113480512 B CN113480512 B CN 113480512B
Authority
CN
China
Prior art keywords
formula
reaction
compound
preparation
compound shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110839803.6A
Other languages
Chinese (zh)
Other versions
CN113480512A (en
Inventor
刘宝彪
张�浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuyang Xinyihua Pharmaceutical Technology Co ltd
Original Assignee
Fuyang Xinyihua Pharmaceutical Technology Co ltd
Fuyang Sineva Material Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuyang Xinyihua Pharmaceutical Technology Co ltd, Fuyang Sineva Material Technology Co Ltd filed Critical Fuyang Xinyihua Pharmaceutical Technology Co ltd
Priority to CN202110839803.6A priority Critical patent/CN113480512B/en
Publication of CN113480512A publication Critical patent/CN113480512A/en
Application granted granted Critical
Publication of CN113480512B publication Critical patent/CN113480512B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54Radicals substituted by oxygen atoms

Abstract

The application relates to the technical field of organic synthesis, and particularly discloses a preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-one, which comprises the steps of using a pepper ring as an initiator, and sequentially carrying out an acylation reaction, a carbonyl protection reaction, a bromination reaction and a carbonyl deprotection reaction to obtain the 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-one. The method simplifies the synthetic route and improves the yield and purity.

Description

Preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-ketone
Technical Field
The application relates to the technical field of organic synthesis, in particular to a preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-one.
Background
1- (7-Bromobenzo [ D ] [1,3] dioxol-4-yl) ethan-1-one (CAS: 1892297-18-6) is an important intermediate in pharmaceutical synthesis, for example: chronic hepatitis C therapeutic drug-cloperavir Hydrochloride (Clopavir Hydrochloride).
However, the synthesis route of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethan-1-one in the related art is long, the yield is low, and the product purity is low.
Disclosure of Invention
In order to simplify the synthetic route and improve the yield and purity, the application provides a preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-ketone, which adopts the following technical scheme:
a preparation method of a compound 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethan-1-one shown as a formula (V) comprises the following steps:
Figure GDA0003548593060000011
preparation of a Compound of formula (II): carrying out lithiation reaction on the compound shown in the formula (I) and n-butyllithium, and then carrying out acylation reaction on the compound and acetyl chloride to obtain a compound shown in a formula (II); the molar ratio of the compound shown in the formula (I), n-butyl lithium and acetyl chloride is 1 (1.8-2.0) to 1.1-1.2;
preparation of a Compound of formula (III): carrying out carbonyl protection reaction on the compound shown in the formula (II) and ethylene glycol under the action of a catalyst to obtain a compound shown in a formula (III); the molar ratio of the compound shown in the formula (II), the glycol and the catalyst is 1 (1.1-1.2) to 0.08-0.10; preparation of a Compound of formula (V): carrying out lithiation reaction on a compound shown in a formula (III) and lithium diisopropylamide, and then carrying out bromination reaction on the compound shown in the formula (III) and bromine to obtain a compound shown in a formula (IV), wherein the molar ratio of the compound shown in the formula (III) to the lithium diisopropylamide to the bromine is (1.4-1.6) to (0.9-1.0); and (3) carrying out carbonyl deprotection reaction on the compound shown in the formula (IV) to obtain the compound shown in the formula (V).
Optionally, in the step of preparing the compound represented by the formula (II), the condition of the lithiation reaction is that the reaction temperature is-80 to-70 ℃.
Optionally, in the preparation of the compound represented by the formula (II) in the step (II), the acylation reaction is performed at a reaction temperature of 20 to 30 ℃.
Optionally, in the step of preparing the compound shown in the formula (III), the catalyst is p-toluenesulfonic acid.
Optionally, in the preparation of the compound shown in the step (III), the carbonyl protection reaction is performed at a reaction temperature of 65-75 ℃.
Optionally, in the step of preparing the compound represented by the formula (IV), the lithiation reaction is carried out under the condition that the reaction temperature is-70 to-80 ℃.
Optionally, in the preparation of the compound shown in the step (IV), the bromination reaction is performed under the condition that the reaction temperature is 20-30 ℃.
Optionally, in the step of preparing the compound represented by the formula (IV), the solvent used for recrystallization is ethyl acetate.
In summary, the present application has the following beneficial effects:
the application not only simplifies the synthetic route of the 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethan-1-one, but also improves the yield and the purity.
Drawings
FIG. 1 is a synthetic scheme of a process for the preparation of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethan-1-one of the present application.
Detailed Description
The present application will be described in further detail with reference to examples.
The synthetic route of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethan-1-one is shown in FIG. 1.
The compound 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-ketone shown in the formula (V) is obtained by using a compound piperonyl shown in the formula (I) as an initiator and sequentially carrying out acylation reaction, carbonyl protection reaction, bromination reaction and carbonyl deprotection reaction.
Preparation of Compound of formula (II)
Figure GDA0003548593060000021
Preparation example 1 of Compound represented by formula (II)
Adding a compound piperonyl (136.0g, 1.114mol) shown in the formula (I) and 200mL of tetrahydrofuran into a reactor, cooling to-78 ℃, dropwise adding n-butyllithium (135.0g, 2.107mol), and reacting at-79 ℃ for 1.5h with heat preservation; then, acetyl chloride (96.3g, 1.226mol) is dripped, the dripping temperature is kept below-79 ℃, then the temperature is slowly raised to 20-30 ℃, and the reaction is carried out for 1.5h under heat preservation. The reaction was quenched by dropping the reaction solution into 150mL of water while maintaining the quenching temperature below 35 ℃ and then sequentially taking 10% by weight of H 2 SO 4 The resulting mixture was washed once with 100mL of the aqueous solution, 200mL of saturated saline solution and 200mL of water, and the mixture was separated to give the compound represented by formula (II) (171.87g, 1.047mol, yield 93.97%).
Preparation example 2 of Compound represented by the formula (II)
Adding the compound piperonyl (136g, 1.114mol) shown in the formula (I) and 200mL of tetrahydrofuran into a reactor, cooling to-78 ℃, dropwise adding n-butyllithium (135g, 2.107mol), and reacting at-79 ℃ for 1.5 h. Acetyl chloride (104.8g, 1.336mol) is dripped, the dripping temperature is kept below-79 ℃, then the temperature is slowly raised to 20-30 ℃, and the reaction is carried out for 1.5h under heat preservation. Dropwise adding the reaction solution into 150mL of water for quenching, and keeping the quenching temperature below 35 ℃; then using H with the weight percentage concentration of 10 percent 2 SO 4 The resulting aqueous solution (100 mL), saturated saline (200 mL) and water (200 mL) were washed once and separated to give a compound represented by formula (II) (169.0g, 1.029mol, yield 92.40%).
Preparation example 3 of Compound represented by formula (II)
A compound, namely piperonyl (136g, 1.114mol) shown in the formula (I) and 200mL of tetrahydrofuran are added into a reactor, n-butyllithium (135g, 2.107mol) is added dropwise after the temperature is reduced to-78 ℃, and the reaction is carried out at-79 ℃ for 1.5 h. Dropwise adding acetyl chloride (96.2g, 1.225mol) and keeping the dropwise adding temperature below-79 ℃, then slowly heating to 20-30 ℃, and carrying out heat preservation reaction for 1.5 h. The reaction was quenched by adding droplets to 150ml of tap water and maintaining the quench temperature below 35 ℃. Then sequentially using H with the weight percentage concentration of 10 percent 2 SO 4 The resulting mixture was washed with 100mL of the aqueous solution, 200mL of saturated saline solution and 200mL of water, followed by separation to give a compound represented by formula (II) (163.67g, 0.997mol, yield 89.50%).
Preparation of Compound of formula (II) comparative example 1
Production comparative example 1 was conducted in contrast to production example 1 except that n-butyllithium (135.0g, 2.107mol) was replaced with lithium diisopropylamide (225.7g, 2.107mol) to obtain a compound represented by formula (II) (87.9g, 0.535mol, yield 68.68%).
Table 1: yield of the Compound of formula (II)
Preparation of the Compound of formula (II) Preparation example 1 Preparation example 2 Preparation example 3 Preparation of comparative example 1
Organic lithium N-butyl lithium N-butyl lithium N-butyl lithium Lithium diisopropylamide
Molar ratio of piperonyl, organolithium and acetyl chloride 1:1.89:1.10 1:1.89:1.20 1:1.89:1.10 1:1.89:1.10
Yield of 93.97% 92.40% 89.50% 68.68%
As is clear from Table 1, the selection of the organolithium reagent has a great influence on the yield of the compound represented by the formula (II).
Preparation of the Compound of formula (III)
Figure GDA0003548593060000041
Preparation example 1 of Compound represented by formula (III)
A compound represented by the formula (II) (127.8g, 0.779mol), ethylene glycol (58g, 0.934mol), p-toluenesulfonic acid (13.8g, 0.080mol) and 300mL of toluene were charged into a reactor and heated to boiling (70 ℃ C.). After the reaction, the temperature is reduced to room temperature, 25g of anhydrous sodium sulfate is added for drying, the mixture is filtered, a filter cake is rinsed by a small amount of toluene, and the compound shown in the formula (III) is obtained after reduced pressure distillation (151.3g, 0.727mol, yield 93.32%).
Preparation example 2 of Compound represented by formula (III)
A compound represented by the formula (II) (125.7g, 0.766mol), ethylene glycol (57.1g, 0.920mol), p-toluenesulfonic acid (13.8g, 0.080mol) and 300mL of toluene were placed in a reactor and heated to boiling (70 ℃ C.). After the reaction, the temperature was reduced to room temperature, 25g of anhydrous sodium sulfate was added, the mixture was dried, filtered, the filter cake was rinsed with a small amount of toluene, and the resulting mixture was distilled under reduced pressure to obtain a compound represented by the formula (III) (149.7g, 0.719mol, yield 93.86%).
Preparation example 3 of Compound represented by formula (III)
300mL of the compound represented by the formula (II) (121.8g, 0.742mol), ethylene glycol (55.3g, 0.891mol), p-toluenesulfonic acid (12.2g, 0.071mol) and toluene were charged into a reactor and heated to boiling (70 ℃ C.). After the reaction, the temperature was reduced to room temperature, 25g of anhydrous sodium sulfate was added, the mixture was dried, filtered, the filter cake was rinsed with a small amount of toluene, and the resulting mixture was distilled under reduced pressure to obtain the compound represented by the formula (III) (148.1g, 0.711mol, yield 95.82%).
Table 2: yield of the Compound of formula (III)
Preparation of the Compound of formula (III) Preparation example 1 Preparation example 2 Preparation example 3
The molar ratio of the compound represented by the formula (II), ethylene glycol and p-toluenesulfonic acid 1:1.20:0.103 1:1.20:0.104 1:1.20:0.096
Yield of 93.32% 93.86% 95.82%
Preparation of Compound represented by the formula (V)
Figure GDA0003548593060000051
Preparation of Compound represented by formula (V) 1
Adding a compound (151.3g, 0.727mol) shown in the formula (III) and 200mL of tetrahydrofuran into a reactor, stirring and cooling to-78 ℃, dropwise adding lithium diisopropylamide (122.5g, 1.144mol) and keeping the dropwise adding temperature below-79 ℃, and preserving heat for reacting for 4 hours after dropwise adding; then adding bromine (116g, 0.726mol) dropwise and keeping the dropwise adding temperature below-79 ℃; after the dropwise addition, heating to 25-30 ℃, and carrying out heat preservation reaction for 2 hours. And (3) dropwise adding the reaction solution into a sodium thiosulfate aqueous solution, extracting with 200mL of ethyl acetate, separating, concentrating the organic phase under reduced pressure until crystals are precipitated, cooling, crystallizing and filtering to obtain the compound shown in the formula (IV).
The compound represented by the formula (IV) is dissolved in 200mL of tetrahydrofuran, 20mL of 1N hydrochloric acid is added, the mixture is stirred, heated and refluxed for 2 hours, then the residue is dissolved in 100mL of ethyl acetate by evaporation under reduced pressure, the obtained solution is washed by water and saturated aqueous solution of sodium chloride in the same volume, finally the obtained solution is dried by magnesium sulfate and the solvent is evaporated to dryness, and the compound represented by the formula (V) is obtained (153.6g, 0.632mol, yield 86.93% and purity 99.2%).
Preparation of Compound of formula (V) 2
Adding the compound shown in the formula (III) (149.7g, 0.719mol) and 200mL of tetrahydrofuran into a reactor, stirring and cooling to-78 ℃, dropwise adding lithium diisopropylamide (115.1g, 1.074mol) and keeping the dropwise adding temperature below-79 ℃, and preserving heat for reacting for 4 hours after dropwise adding. Bromine (109g, 0.682mol) was then added dropwise while maintaining the addition temperature below-79 ℃. And heating the mixture to 25-30 ℃, and reacting for 2 hours under the condition of heat preservation. Adding the reaction solution into an aqueous solution of sodium thiosulfate dropwise, extracting with 200mL of ethyl acetate, separating, concentrating the organic phase under reduced pressure until crystals precipitate, cooling, and filtering to obtain the compound shown in the formula (IV).
The compound represented by the formula (IV) is dissolved in 200mL of tetrahydrofuran, 20mL of 1N hydrochloric acid is added, the mixture is stirred, heated and refluxed for 2 hours, then the residue is dissolved in 100mL of ethyl acetate by evaporation under reduced pressure, the obtained solution is washed by water and saturated aqueous solution of sodium chloride in the same volume, finally the obtained solution is dried by magnesium sulfate and the solvent is evaporated to dryness, and the compound represented by the formula (V) is obtained (148.1g, 0.609mol, the yield is 84.70%, and the purity is 99.3%).
Preparation of Compound represented by the formula (V) 3
Adding the compound (148.1g, 0.711mol) shown in the formula (III) and 200mL of tetrahydrofuran into a reactor, stirring and cooling to-78 ℃, slowly dropwise adding lithium diisopropylamide (119.9g, 1.119mol) while keeping the dropwise adding temperature below-79 ℃, and preserving heat for reacting for 4 hours after dropwise adding. Bromine (110.1g, 0.689mol) was then added dropwise while maintaining the dropping temperature below-79 ℃. The mixture is heated to 25-30 ℃ and the reaction is carried out for 2 hours under the condition of heat preservation. Adding the reaction solution into sodium thiosulfate aqueous solution dropwise, extracting with 200ml ethyl acetate, separating, concentrating the organic phase under reduced pressure until crystals precipitate, cooling, and filtering to obtain the compound shown in formula (IV).
The compound represented by the formula (IV) is dissolved in 200mL of tetrahydrofuran, 20mL of 1N hydrochloric acid is added, the mixture is stirred, heated and refluxed for 2 hours, then the residue is dissolved in 100mL of ethyl acetate by evaporation under reduced pressure, the obtained solution is washed by water and saturated aqueous solution of sodium chloride in the same volume, finally the obtained solution is dried by magnesium sulfate and the solvent is evaporated to dryness, and the compound represented by the formula (V) is obtained (152.6g, 0.628mol, yield 88.33% and purity 99.2%).
Preparation of Compound of formula (V) comparative example 1
Production comparative example 1 was conducted in contrast to production example 1 except that lithium diisopropylamide (122.5g, 1.144mol) was replaced with n-butyllithium (73.3g, 1.144mol) to obtain a compound represented by formula (V) (90.2g, 0.371mol, yield 51.03%, purity 97.5%).
Confirmation of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethan-1-one represented by formula (V):
1 H-NMR(300MHz,DMSO-d 6 ):δ7.47(d,1H),7.133(d,1H),6.07(s,2H),2.62(s,3H);
MZ:m/z:241.96。
table 3: yield of the Compound of formula (V)
Figure GDA0003548593060000061
As is clear from table 3, in the production step of the compound represented by formula (V), the kind of the organolithium reagent has a great influence on both the yield and the purity of the compound represented by formula (V).
As can be seen from the yields in tables 1-3, the total yield of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethan-1-one synthesized by the preparation method provided by the application can reach 87.28% at most, and the purity is more than 99%.
The present embodiment is only for explaining the present application, and it is not limited to the present application, and those skilled in the art can make modifications of the present embodiment without inventive contribution as needed after reading the present specification, but all of them are protected by patent law within the scope of the claims of the present application.

Claims (6)

1. A preparation method of a compound 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethan-1-one shown as a formula (V) is characterized by comprising the following steps:
Figure FDA0003628518760000011
Preparation of a Compound of formula (II): carrying out lithiation reaction on a compound shown in a formula (I) and n-butyllithium, and then carrying out acylation reaction on the compound and acetyl chloride to obtain a compound shown in a formula (II); the molar ratio of the compound shown in the formula (I), n-butyl lithium and acetyl chloride is 1 (1.8-2.0) to 1.1-1.2;
preparation of a Compound of formula (III): carrying out carbonyl protection reaction on the compound shown in the formula (II) and ethylene glycol under the action of a catalyst to obtain a compound shown in a formula (III); the molar ratio of the compound shown in the formula (II), the glycol and the catalyst is 1 (1.1-1.2) to 0.08-0.10;
preparation of a Compound of formula (V): carrying out lithiation reaction on the compound shown in the formula (III) and lithium diisopropylamide, and carrying out bromination reaction on the compound shown in the formula (III) and bromine to obtain a compound shown in a formula (IV), wherein the molar ratio of the compound shown in the formula (III) to the lithium diisopropylamide to the bromine is 1 (1.4-1.6) to 0.9-1.0; carrying out carbonyl deprotection reaction on the compound shown in the formula (IV) to obtain a compound shown in a formula (V);
in the preparation of the compound shown in the step (III), the catalyst is p-toluenesulfonic acid.
2. The method according to claim 1, wherein the lithiation reaction is carried out at a reaction temperature of-80 to-70 ℃ in the preparation of the compound represented by the formula (II).
3. The method according to claim 1, wherein the acylation reaction is carried out at a temperature of 20 to 30 ℃ in the preparation of the compound represented by the formula (II).
4. The method according to claim 1, wherein the carbonyl protection reaction is carried out at a reaction temperature of 65-75 ℃ in the preparation of the compound represented by the formula (III).
5. The process according to claim 1, wherein the lithiation reaction is carried out at a reaction temperature of-70 to-80 ℃ in the production of the compound represented by the formula (V).
6. The preparation method according to claim 1, wherein in the preparation of the compound represented by the formula (V), the bromination reaction is carried out at a reaction temperature of 20-30 ℃.
CN202110839803.6A 2021-07-23 2021-07-23 Preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-ketone Active CN113480512B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110839803.6A CN113480512B (en) 2021-07-23 2021-07-23 Preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-ketone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110839803.6A CN113480512B (en) 2021-07-23 2021-07-23 Preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-ketone

Publications (2)

Publication Number Publication Date
CN113480512A CN113480512A (en) 2021-10-08
CN113480512B true CN113480512B (en) 2022-07-29

Family

ID=77942380

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110839803.6A Active CN113480512B (en) 2021-07-23 2021-07-23 Preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-ketone

Country Status (1)

Country Link
CN (1) CN113480512B (en)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659144A (en) * 2002-04-02 2005-08-24 舍林股份公司 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
CN101157679A (en) * 2007-11-15 2008-04-09 上海化学试剂研究所 Method for preparing N- ethyl-3,4-(methylenedioxy) aniline
WO2009064251A1 (en) * 2007-11-15 2009-05-22 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy 066
CN108675998A (en) * 2018-06-28 2018-10-19 北京凯因科技股份有限公司 A kind of crystallinity methyl carbamate class compound
CN108904496A (en) * 2018-06-28 2018-11-30 北京凯因科技股份有限公司 For treating the pharmaceutical composition of hepatitis C infection
CN109419806A (en) * 2017-08-23 2019-03-05 南京圣和药业股份有限公司 Antiviral composition and its application
WO2019200005A1 (en) * 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
CN111072625A (en) * 2019-12-06 2020-04-28 浙江理工大学 Preparation method of 3, 4-methylenedioxyacetophenone
WO2020117966A1 (en) * 2018-12-05 2020-06-11 Atea Pharmaceuticals, Inc. Highly active drug combination for treatment of hepatitis c virus
CN112358462A (en) * 2020-11-10 2021-02-12 成都伊诺达博医药科技有限公司 Synthetic method of piperonyl derivatives
CN113603670A (en) * 2021-07-23 2021-11-05 阜阳欣奕华制药科技有限公司 Method for preparing 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-one

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659144A (en) * 2002-04-02 2005-08-24 舍林股份公司 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
CN101157679A (en) * 2007-11-15 2008-04-09 上海化学试剂研究所 Method for preparing N- ethyl-3,4-(methylenedioxy) aniline
WO2009064251A1 (en) * 2007-11-15 2009-05-22 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy 066
CN109419806A (en) * 2017-08-23 2019-03-05 南京圣和药业股份有限公司 Antiviral composition and its application
WO2019200005A1 (en) * 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
CN108675998A (en) * 2018-06-28 2018-10-19 北京凯因科技股份有限公司 A kind of crystallinity methyl carbamate class compound
CN108904496A (en) * 2018-06-28 2018-11-30 北京凯因科技股份有限公司 For treating the pharmaceutical composition of hepatitis C infection
WO2020001089A1 (en) * 2018-06-28 2020-01-02 北京凯因格领生物技术有限公司 Crystalline methyl carbamate compound
WO2020117966A1 (en) * 2018-12-05 2020-06-11 Atea Pharmaceuticals, Inc. Highly active drug combination for treatment of hepatitis c virus
CN111072625A (en) * 2019-12-06 2020-04-28 浙江理工大学 Preparation method of 3, 4-methylenedioxyacetophenone
CN112358462A (en) * 2020-11-10 2021-02-12 成都伊诺达博医药科技有限公司 Synthetic method of piperonyl derivatives
CN113603670A (en) * 2021-07-23 2021-11-05 阜阳欣奕华制药科技有限公司 Method for preparing 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-one

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
盐酸可洛派韦在HCV感染者中的耐受性和药代动力学;娄金凤等;《临床肝胆病杂志》;20210630;第37卷(第6期);第1304-1308页 *

Also Published As

Publication number Publication date
CN113480512A (en) 2021-10-08

Similar Documents

Publication Publication Date Title
AU2002224131A1 (en) Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound
US20100249439A1 (en) Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
CN112062712A (en) Preparation method of 2- (5-bromo-3-methylpyridin-2-yl) acetic acid hydrochloride
US7057058B2 (en) Process for the preparation of 13-cis-retinoic acid
CN113480512B (en) Preparation method of 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-ketone
CN106928149B (en) Preparation method of olaparib
CN113603670B (en) Method for preparing 1- (7-bromobenzo [ D ] [1,3] dioxol-4-yl) ethyl-1-one
CN114014864B (en) Preparation process of traasiril compound
CN108586529A (en) A kind of chipal compounds and the preparation method and application thereof containing biphenyl backbone
CN110590601B (en) Synthesis method of malononitrile
CN113024375A (en) Preparation method of trans, trans-4-alkyl-4' -pentyl-3 (E) ene-bicyclohexane liquid crystal monomer
CN112341313A (en) Preparation method of 3, 5-dichlorobenzyl alcohol and carboxyamidotriazole intermediate
CN112028874A (en) Synthesis method of eritinib
WO2016115962A1 (en) Preparation method for nebivolol intermediate and preparation method for nebivolol
US3268541A (en) Process for producing 2-phenyl-(or substituted 2-phenyl-) 1, 3-di (4-pyridyl)-2-propanols
CN108864185B (en) β -phosphonoenamine derivatives and process for their preparation
CN112279805B (en) Process for preparing 1- (3-methoxypyridin-2-yl) -2-propanone
CN109206465B (en) Method for synthesizing adenosine cyclophosphate
KR101974388B1 (en) Alkyl diethylene triamine derivatives and a process of the preparation thereof
CN116621754A (en) Process for preparing pyrrolidone-3-beta' -amino derivatives
CN114292297A (en) Method for preparing antiviral drug tenofovir alafenamide fumarate
JP4004082B2 (en) Method for producing cyclic nitroguanidine derivatives
CN116606236A (en) Synthesis method of 6-benzyloxy tryptophan
CN115181142A (en) Crystal form of salidroside and preparation method thereof
CN114394941A (en) Preparation method of 2, 4-diamino-6-chloropyrimidine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20231218

Address after: 236600 intersection of Yingyang road and Chuangye Road, Taihe Economic Development Zone, Fuyang City, Anhui Province (declaration and commitment)

Patentee after: Fuyang xinyihua Pharmaceutical Technology Co.,Ltd.

Address before: 236600 intersection of Yingyang road and Chuangye Road, Taihe Economic Development Zone, Fuyang City, Anhui Province (declaration and commitment)

Patentee before: Fuyang xinyihua Pharmaceutical Technology Co.,Ltd.

Patentee before: FUYANG SINEVA MATERIAL TECHNOLOGY Co.,Ltd.

TR01 Transfer of patent right